Skip to main content
TipRanks
Go Ultimate75% OFF

Purple Biotech (PPBT) AI Stock Analysis

1,167 Followers
PPBT

Purple Biotech

(NASDAQ:PPBT)

Select Model
Rating:49Neutral
Price Target:$1.50â–¼(-7.98% Downside)
Action:reiterated
Date:11/13/26

The score is primarily weighed down by weak financial performance (minimal revenue, large losses, and ongoing cash burn despite low debt). Technicals provide some support via improving short-term momentum and price strength versus shorter moving averages, but valuation remains unfavorable due to negative earnings and no dividend yield data.

Positive Factors
Low LeverageVery low leverage reduces refinancing and solvency pressure while preserving financial flexibility for clinical development. Although the company is loss-making, its limited debt burden avoids adding substantial interest obligations or mandatory repayment demands during the commercialization process.
Negative Factors
No Meaningful RevenueThe absence of meaningful revenue confirms that Purple Biotech remains pre-commercial and lacks a recurring operating base to fund research internally. Until an asset reaches commercialization or a partnership generates material income, financial performance will remain highly dependent on pipeline progress and external capital.

Purple Biotech (PPBT) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%PPBT-79.65%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$225.08K
Dividend Yield
―
Average Volume (3M)
1.26M
Price to Earnings (P/E)
-0.7
Beta (1Y)
0.82
Revenue Growth
―
EPS Growth
-151.47%
Country
US
Employees
10
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Purple Biotech Business Overview & Revenue Model

Company Description

Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline fea...

Purple Biotech Financial Statement Overview

Summary

Financial performance is weak: revenue is effectively nonexistent across recent periods, losses remain sizable (TTM net income about -24.6M), and cash flow is consistently negative (TTM operating/free cash flow about -7.76M). The main offset is low leverage with minimal debt (~0.13M TTM), but equity has declined sharply over time, reflecting ongoing burn and capital erosion.

Income Statement

9Very Negative

Balance Sheet

58Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-24.28M-26.25M-7.05M-19.72M-21.49M-17.52M
Net Income-24.49M-26.39M-7.24M-19.88M-21.67M-18.38M
Balance Sheet
Total Assets14.17M17.57M37.04M44.30M54.62M70.20M
Cash, Cash Equivalents and Short-Term Investments6.11M9.57M8.52M15.41M32.11M47.20M
Total Debt134.00K244.00K183.00K351.00K515.00K749.00K
Total Liabilities1.95M7.91M4.13M10.01M7.52M5.09M
Stockholders Equity12.27M9.71M32.86M34.21M46.91M64.83M
Cash Flow
Free Cash Flow-7.76M-5.54M-14.37M-19.93M-16.96M-15.37M
Operating Cash Flow-7.76M-5.54M-14.37M-19.93M-16.73M-15.25M
Investing Cash Flow314.00K449.54K509.00K13.88M19.91M13.41M
Financing Cash Flow7.92M6.41M6.77M5.45M1.11M1.51M

Purple Biotech Technical Analysis

Technical Analysis SentimentPositive
Last Price1.63

Price Trends

50DMA1.39Positive
100DMA1.47Positive
200DMA2.77Negative

Market Momentum

MACD0.05Negative
RSI69.93Neutral
STOCH99.39Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPBT, the sentiment is Positive. The current price of 1.63 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.39, and below the 200-day MA of 2.77, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 69.93 is Neutral, neither overbought nor oversold. The STOCH value of 99.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PPBT.

Purple Biotech Risk Analysis

Purple Biotech disclosed 77 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Any impairment in the value of our intangible assets, including goodwill, could negatively affect our operating results and total capitalization.Q4, 2025
2.The rapid development of artificial intelligence may negatively affect our business.Q4, 2025
3.We may not have sufficient patent terms to effectively protect our products and business.Q4, 2025

Purple Biotech Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PPBT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PPBTPPBT49Neutral$10.08M-0.73-151.94%――-151.47%
TCRTTCRT45Neutral$6.73M-0.83-232.60%―-50.00%20.95%
KALAKALA28Underperform$2.68M-0.00-222.32%――78.25%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%PPBTTCRTOGENPMCBKALADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PPBT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PPBTPurple Biotech Ltd.1.63-5.57-77.37%
TCRTAlaunos Therapeutics Inc1.63-1.59-49.38%
OGENOragenics Inc0.20-0.91-81.89%
PMCBPharmacyte Biotech, Inc.6.68-7.10-51.51%
KALAKala Bio, Inc.0.14-34.81-99.61%

Purple Biotech Corporate Events

Purple Biotech Reinstates Isaac Israel as Interim CEO in Leadership Reshuffle

Oct 5, 2026

Purple Biotech announced that its board appointed director and former chief executive Isaac Israel as interim CEO, effective October 5, 2026, as it searches for a permanent chief executive. Israel previously led the company from 2012 to 2022, briefly...

Purple Biotech Shareholders Approve All AGM Proposals, File Results with U.S. SEC

Sep 9, 2026

Purple Biotech reported that shareholders approved all proposals presented at its Annual General Meeting held on September 8, 2026, at the company’s offices in Rehovot. The resolutions, passed in accordance with Israeli Companies Law and the firm’s a...

Purple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform

Sep 2, 2026

On September 2, 2026, Purple Biotech reported that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering precursor tri-specific antibody constructs and methods of use. The allowance expands protection for...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026